The cluster shows a clear divergence: large European asset managers are reducing exposure while Barclays and smaller managers are adding. Monitor next 13F for continuation of this trend and any insider buying that could corroborate institutional conviction.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $321.46entry
- T+1 · 6d ago +0.08%α −1.24% · $321.72
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Institutional activity in Penumbra during Q3 2026 was mixed: 8 buyers added $18.0M in new positions while 5 sellers reduced holdings by $66.1M. The net selling pressure of $48.1M is dominated by three large European asset managers (Natixis, Amundi, New York Life) trimming or nearly exiting, likely reacting to the pending Boston Scientific acquisition and the mixed Q3 earnings (revenue beat, EPS miss). No insider buying corroborates the institutional moves.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$48.1M
▲ Buyers (8)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Barclays | ADD | +77.7% | $26.6M | $11.7M |
| Alberta Investment Management | ADD | +35.8% | $14.3M | $3.9M |
| Exchange Traded Concepts | DOUBLED | +126.8% | $2.3M | $1.3M |
▼ Sellers (5)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Amundi | NEAR_EXIT | -88.2% | $34.7M | -$30.6M |
| Natixis | TRIM | -72% | $39.3M | -$28.2M |
| New York Life Investment Management | TRIM | -74.2% | $6.7M | -$5.0M |
Key Facts
- 8 institutional buyers added $18.0M in new positions; 5 sellers reduced by $66.1M
- Net institutional selling of $48.1M in Q3 2026
- Top seller: Amundi near-exited 88.2% of its position ($30.6M reduction)
- Top buyer: Barclays added $11.7M (+77.7% increase)
- No insider open-market buying in the window (confluence score 34/100, institutions_only)
- Filing follows Oct 29 earnings: revenue beat consensus but EPS missed; no guidance due to pending Boston Scientific acquisition
Financial Impact
Net institutional selling of $48.1M in Q3 2026, with $66.1M in total reductions vs $18.0M in additions
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Pending Boston Scientific acquisition creates uncertainty and may limit institutional appetite
- No insider buying to corroborate the bullish side of the cluster
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-PEN-2026-Q3 |
Track record
11 reports on PEN
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Viewing Entry $321.46 settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 settles Feb 4
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 settles Jan 28
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $321.19 to $325.22 ▼ −1.25% +1.20% vs SPY
- May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 ▼ −0.50% −4.34% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 ▲ +0.50% +4.34% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 ▼ −2.14% −5.25% vs SPY
- Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 ▼ −3.94% −10.71% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $330.36 to $315.75 ▼ −4.42% −18.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers